Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Dimerix Limited ( (AU:DXB) ) has provided an update.
Dimerix Limited has announced the quotation of 865,992 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is engaged in the research and development of pharmaceutical products, with a particular emphasis on renal and respiratory diseases.
Average Trading Volume: 3,168,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$324M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue